established a Scientific Advisory Board (SAB) and has appointed
Adial Pharmaceuticals, Inc. today announced that it has established a Scientific Advisory Board (SAB) and has appointed Dr. Giovanni Addolorato, a leading global expert in the field of alcohol use disorder (AUD), as its first member and Chairperson. The SAB will help to guide the Company’s strategy and advance AD04, its lead therapeutic agent for AUD, with Phase 3 trials expected to commence in the first half of 2019.
globenewswire.com/news-release/2018/11/29/1659033/0/en/Adial-Pharmaceuticals-Establishes-Scientific-Advisory-Board-and-Appoints-Global-Thought-Leader-in-the-Field-of-Alcohol-Use-Disorder.html
seekingalpha.com/news/3413224-adial-pharmaceuticals-tonix-pharmaceuticals-among-healthcare-gainers-restoration-robotics
globenewswire.com/news-release/2018/11/29/1659033/0/en/Adial-Pharmaceuticals-Establishes-Scientific-Advisory-Board-and-Appoints-Global-Thought-Leader-in-the-Field-of-Alcohol-Use-Disorder.html
seekingalpha.com/news/3413224-adial-pharmaceuticals-tonix-pharmaceuticals-among-healthcare-gainers-restoration-robotics
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.